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Introduction: The present study aimed to determine (a) the correlation 
between type and number of stressful life events and quality of life in 
patients with medication-overuse headache (MOH) and (b) whether 
stressful life events could be attributed to medication overuse and the 
conversion of headache to a chronic type.
Methods: The present study included 114 patients aged between 15 and 
65 years who met the criteria for headache classification of International 
Headache Society (IHS). The patients were divided into three groups 
according to the revised 2004 IHS classification; MOH (n=64), chronic 
migraine (n=25) and episodic migraine (n=25). Detailed data on clinical 
and sociodemographic characteristics were recorded. Neurological and 
physical examinations were performed for differential diagnosis. The 
patients underwent structured clinical interviews for DSM-IV Inventory 
(SCID-I), Beck Anxiety Inventory, Beck Depression Inventory, Short 
Form-36 (SF-36) and Life Events List. Scores of these inventories were 
statistically compared.
Results: Comparing MOH group with episodic migraine group via SF-
36, statistically significant decreases were observed in the subscales of 
physical role limitation (p=.024), pain (p=.0001), general health (p=.043) 
and social functioning (p=.004). There was a statistically significant 
correlation between the number of life events and the time the disease 
became chronic in the patient group with non-MOH chronic migraine 
(p=.027). Moreover, a statistically significant correlation was observed 
between stressful family life events and the body pain subscale of quality 
of life scale (p=.038).
Conclusion: The present study demonstrates that stressful life events 
impair quality of life in patients with MOH. It was also found that number 
of stressful life events could be attributed to the conversion of headache 
to a chronic type.  
Keywords: Medication-overuse headache, stressful life events, quality 
of life
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INTRODUCTION
Migraine is a heterogeneous group of diseases characterized by migraine attacks that significantly impair quality of life and cause disability. 
It is a common condition affecting approximately 10% of the population (16% females and 5% males). According to the classification 
of International Headache Society (IHS), chronic migraine (CM) is included in the complications of migraine (1). Chronic migraine is 
reported to affect 1%–3% of the general population (2). Diagnosis is made if headache is present for ≥15 days in a month and for at least 
3 months, average headache duration is ≥4 h in a day and ≥8 days of this pain is associated with migraine. Risk factors for conversion of 
headache to a chronic type from an episodic type include hypertension, surgical menopause, caffeine abuse, obesity, smoking, snoring, 
sleep apnea, suicide risk and psychiatric comorbidities (3).
Medication-overuse headache (MOH) was first defined by the International Headache Society (IHS) in 2004. According to the addition-
al diagnostic criteria published in 2006 by IHS, MOH is defined as headache that is present for ≥15 days in a month and for ≥3 months, 
requiring the use of medications, such as analgesics, barbiturates, opioids, ergot derivatives, caffeine, triptans and aspirin, for >10 days 
in a month (1,4). Prevalence of MOH in the general population is reported to be 1%–1.5% and it accounts for 30%–50% of patients 
admitted to headache clinics (5,6). 
Migraine is a chronic disorder that unfavorably affects patients’ social, occupational and personal quality of life. In a previous study, quality 
of life was found to be significantly impaired in migraine patients compared with healthy individuals as well as patients suffering from 
chronic conditions such as diabetes, arthritis and back pain (7). Significant impairment in many subgroups of quality of life in patients with 
chronic migraine, MOH and chronic cluster headache has been reported (8). Similar results were obtained also in the studies conducted 
in various populations and cultures, such as China, Italy, Spain, United Kingdom and USA, revealed similar results and quality of life in 
affected individuals was found to be poor (9,10,11,12,13). 
In the literature, number of studies that have studied quality of life in 
patients with MOH is quite limited. Comparing chronic daily headache 
patients with and without medication-overuse and have, quality of life 
was found to be lower in those with MOH (9,10,14,15). Studies revealed 
significant impairment in quality of life in all types of migraine compared 
with the healthy individuals and impairment was determined to be higher 
in patients with MOH. 
It has been reported that stress has an important role in the occurrence 
of pain in 39% patients with headache (16). Internal or external stress fac-
tors activate the sympathetic nervous system and hypothalamic–pituitary–
adrenal axis and may lead to stress-related reactions of the body. The 
degree of this response depends on the duration, severity and frequency 
of exposure to stress. It has been found that psychological stress is effec-
tive not only in the initiation of migraine but also in the conversion to the 
chronic type from the episodic type (17,18,19,20). Moreover, it was found 
that daily hassles are more common than major life events in patients with 
chronic headache and that minor life events are significantly associated 
with the frequency and intensity of headache (21,22). It was determined 
that stress significantly impairs quality of life in patients with chronic daily 
headache (23). In addition, it was found that anxiety and depression play 
an important role in the conversion of migraine to MOH (24,25). 
In the present study of MOH patients, our aims were as follows:
1) Assess the correlation between number of stressful life events and 
quality of life; 
2) Investigate the correlation between stressful life events and subgroups 
of quality of life by classifying stressful life events; 
3) Determine whether psychiatric comorbidities play a role as significant 
as medication overuse in the conversion of headache to a chronic 
type; 
4) Different from the previous studies, determine correlation between 
different psychiatric comorbidities and quality of life. 
METHODS
The present study was approved by the Baskent University Ethics Com-
mittee (project no: KA 12/257) and supported by Baskent University Re-
search Fund. 
The study included 114 patients admitted to Baskent University, Facul-
ty of Medicine, Adana Medical Center, Outpatient Clinic of Neurology 
between September 2012 and February 2014 with the complaint of 
headache and diagnosed with headache based on the IHS 2004 diagnostic 
criteria. All patients were informed about the aim and method of the 
study and their written consents were obtained. Fourteen patients with 
psychotic disorders, mental retardation, severe neurological disease, or 
secondary headache; those who disagreed to participate in the study; and 
those aged <18 years were excluded from the study. 
The neurologists completed the neurological-disease related sections of 
the sociodemographic data form and performed detailed neurological 
examinations. Organic causes were excluded using appropriate methods. 
The diagnoses of MOH, CM and episodic migraine (EM) were made ac-
cording to the IHS diagnostic criteria. After these evaluations, three types 
of migraine were determined on the basis of IHS-II criteria; MOH (n=64), 
CM (n=25) and EM (n=25).
The diagnosis of MOH was made if headache persisted for >15 days in 
a month, analgesics have been used for >3 months, headache worsened 
during analgesic use and if headache notably improved or returned into 
previous type in 2 months after analgesic discontinuation.
Based on the IHS classification, overused medications were classified into 
ergotamines, triptans, pain relievers, opioids, analgesic combinations, com-
bination of acute medications and others. 
After neurological examinations, the patients were examined by a psychi-
atrist. Psychiatrist examined the patients without knowing the patients’ 
headache type. The psychiatrist completed the psychiatric disease-relat-
ed sections in the sociodemographic data form. Psychiatric comorbidities 
were diagnosed using a structured clinical interview for DSM-IV.
Patients completed the rest of the sociodemographic data form, SCID-I, 
Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Short-
Form-36 Quality of Life Scale (SF-36) and Life Events List (LEL). 
Sociodemographic data form: Sociodemographic data form was 
completed by psychiatrists, neurologists and the patients. It included the 
age, sex, marital status, occupation, history of psychiatric disease and 
family history of patients. 
SCID-I: It is a structured clinical interview performed by the interviewer 
to investigate axis-I psychiatric disorders. It consists of six modules and 
investigates diagnostic criteria of a total of 38 axis-I disorders. Two mod-
ules are used for mood episodes and mood disorders, two modules are 
used for psychotic symptoms and psychotic disorders and one of the two 
modules is used for anxiety disorders and the other was used for sub-
stance abuse and other disorders. It was developed in 1997 by First et 
al. (26). It’s Turkish version has been validated by Ozkurkcugil et al. (27) 
under the name of Structured Clinical Interview For DSM-IV Axis-I Disorders. 
BDI: It is a self-rating scale developed by Beck (28). This scale consists of 
21 questions, each including 4 situations. Each answer is rated between 0 
and 3 and total score changes between 0 and 63. Total score is interpreted 
as follows: 0–4 no/minimum depression, 10–16 mild depression, 17–29 
moderate depression and 30–63 severe depression. Validity and reliability 
study of Turkish version of the scale was conducted by Hisli et al. (29); 
a score of ≥17 is considered as major depression in Turkish population. 
BAI: It is a 21-item scale developed by Beck et al. (30) and is widely 
used to measure anxiety severity. It has acceptable validity and reliability in 
various populations. Each item is scored between 0 and 3 and severity of 
anxiety increases as the score increases. Scores given to each of these 21 
items are added at the end of psychiatric evaluation. Validity and reliability 
study of Turkish version was performed by Ulusoy et al. (31).
SF-36: It is a self-rating scale widely used to evaluate quality of life. In this 
scale, eight dimensions of health [physical functioning, role limitation (due 
to physical and emotional problems), social functioning, mental health, vi-
tality (energy), body pain and general health], distributed in 36 items, are 
investigated. SF-36 was developed in 1992 by Ware et al. (32). In 1999, 
Kocyigit et al. adapted it into Turkish and conducted a study of the validity 
and reliability the version (33).
LEL: This list was developed by Sorias (34) and it has been adapted to the 
Turkish population. Sorias’s life events consist of 107 items. These events 
mainly include economic status, health status, education, occupation, rela-
tionship with family, close relatives and friends, sexual life, loss (economic, 
health, spouse) and change of place. According to the study nature, it 
can be used by selecting certain events out of the list. The number of 
life events was evaluated in four groups: 0: no life event; group 1: 1–5 life 
events, group 2: 6–10 life events; group 3: ≥11 life events. Scores of the 
scales were compared between these groups. Moreover, events in LEL 234
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were divided into four categories as economic, familial, health and per-
sonal and these events were compared with the scores of other scales. 
Statistical Analysis
Statistical analysis of data was performed using Statistical Package for 
the Social Sciences (SPSS Inc., Chicago, IL, USA) 17.0 software package. 
Continuous measurements were summarized as mean and standard de-
viation (or minimum–maximum where necessary), whereas categorical 
variables were summarized as n (%). The chi-square test was used for 
comparing categorical variables between the groups. Continuous variables 
were compared between the groups after checking the distribution of 
these variables. Student t-test was used for normally distributed variables, 
whereas Mann–Whitney U test was used for variables not distributed 
normally. Repeated measures analysis was used for the comparison of 
pre-treatment and post-treatment test results. The level of statistical sig-
nificance was considered to be 0.05 for all tests.
RESULTS
Sociodemographic data are summarized in Table 1. A total of 114 mi-
graine patients were included in the study. The patients were divided into 
three groups as MOH (n=64), CM (n=25) and EM (n=25). The mean 
age of patients with MOH was 37±10.2 (17–60) years. There was no 
significant difference between three groups in terms of gender, education 
level, marital status, headache duration, severity of headache [visual analog 
scale (VAS)] and smoking habit. Moreover, no significant difference was 
determined in terms of symptoms of headache-associated vomiting, nau-
sea, photophobia and osmophobia.
The duration of chronic headache (month) and number of days with head-
ache in a month were statistically significantly higher in the MOH and CM 
groups than in the EM group (p=.0001). The mean number of analgesics 
received in a month was 30 (6–80) in MOH, 5 (0–30) in CM and 3 (1–8) 
in EM groups; the difference was statistically significantly higher in MOH 
group (p=.001). The most frequently received medications in the MOH 
group were simple analgesics (70.3%) and non-steroidal anti-inflammatory 
agents (70.3%), followed by triptans (23.5%) and ergot alkaloids (15.6%).
Comparison between migraine groups in terms of 8 SF-36 subscales re-
vealed that quality of life was statistically significantly impaired in the fields 
of role-physical (p=.024), body pain (p=.0001), general health (p=.043) 
and social functioning (p=.004) in the MOH group compared with the 
EM group. When EM and CM groups were compared, statistically signifi-
cant difference was found only in the social functioning subscale of SF-36 
(p=.04). There was no statistically significant difference between MOH 
and CM groups in terms of quality of life (Table 2).
The number of events in LEL, which consists of 107 items, was evaluated 
by dividing the study participants into 4 groups; group 0: no event, group 
1: 1–5 events, group 2: 6–10 events and group 3: ≥11 events. In the MOH 
group, 1–5 life events were present in 50% (n=32), 6–10 life events were 
present in 43.8% (n=28) and ≥11 life events were present in 4.7% (n=3) 
patients. There was no statistically significant difference between the CM, 
EM and MOH groups in terms of number of life events (Table 3). No 
statistically significant difference was found between the number of life 
events and headache duration (year), time to convert to a chronic type 
(year) and VAS scores in the MOH and EM groups (p>.05). In the CM 
group without MOH, statistically significant difference was determined 
between the number of life events and time to convert to a chronic type 
(p=.027) (Table 4). 
Comparing mean number of life events and quality of life, statistically 
significant difference was observed in the body pain (p=.002) and social 
functioning (p=.013) sub-scales of SF-36 (Table 4).
In the analysis of LEL according to the groups, the most frequently en-
countered life events in MOH patients were trouble with chief and 
colleagues (n=7, 12.28%), change in sleeping habits (n=32, 56.14%), 
extreme borrowing (n=10, 17.54%), menopause (n=17, 29.82%), pres-
ence of severe illness, occurrence of an accident (n=10, 17.54%), major 
change in living conditions and social activities (n=19, 33.13%), marital 
problems (n=14, 24.56%) and conflict with mother or father (n=6, 
10.53%) (Table 5).
Parameters in LEL were divided into 4 categories as economic, personal, 
familial and health. Of the patients with MOH, 42.2% (n=27) had familial, 
84.4% (n=54) had personal, 53.1% (n=34) had health and 35.9% (n=23) 
had economic stressful life events. No correlation was found between the 
type of stressful life event and headache duration and VAS score. Statis-
tically significant correlation was found only between stressful family life 
events and the body pain subscale of SF-36 (p=.038) (Table 6).
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Table 1. Comparison of the groups according to sociodemographic characteristics, headache profile and anxiety, depression scale score
 MOH (n=64) CM (n=25) EM (n=25)
 Median   Median  Median   p group  p group  p group  
 (Min-Max) (Min-Max) (Min-Max) p 1 and 2 1 and 3 2 and 3
Age (year) 37 (17-60) 30 (17-47) 38 (20-61) .050 .021 .978 .059
Education (year) 11 (5-17) 10 (5-17) 11 (5-17) .284 .519 .115 .435
BAI 20 (3-46) 16 (7-56) 16 (2-46) .784 .823 .563 .521
BDI 17 (4-55) 19 (4-36) 13 (2-28) .520 .815 .265 .428
Headache duration (year) 10 (1-40) 7 (1-30) 7 (1-35) .377 .182 .557 .400
Chronic headache duration (month) 6 (1-48) 4 (0-24) 0 (0-6) .0001 .247 .0001 .0001
Frequency of headache (days/month) 30 (18(30) 25 (20-30) 3 (1-25) .0001 .152 .0001 .0001
VAS 9 (1-10) 8 (5-10) 8 (7-10) .063 .097 .035 .956
The number of analgesics  30 (6-80) 5 (0-30) 3 (1-8) .001 .0001 .0001 .092
p: Kruskal–Wallis test (p<.05). p group 1 and 2, p group 1 and 3, p group 2 and 3: Post-hoc Mann–Whitney U test (p≤.017 Bonferroni correction). MOH: medication-overuse headache; 
CM: chronic migraine; EM: episodic migraine; BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; VAS: visual analog scale
Psychiatric comorbidity was present in 65.6% (n=42) of the patients with 
MOH, 52% (n=13) of the patients with CM and 44.4% (n=12) of the pa-
tients with EM. Psychiatric comorbidity was statistically significantly higher 
among those with MOH (p=.042). Of the patients with MOH, 21.9% had 
depression, 35.9% had anxiety disorder and 7.8% had somatoform disor-
der. Among anxiety disorders, the prevalence of obsessive–compulsive 
disorder was 21.1%. Of the patients with episodic migraine, 14.89% had 
depression, 18.5% had anxiety disorder and 11.1% had somatoform disor-
der. There was no statistically significant difference between the groups in 
terms of psychiatric comorbidities (p>.05).
DISCUSSION
This study, which was conducted to investigate the effect of stressful life 
events on quality of life patients with MOH, determined correlations 
between pain and number of life events and familial stressful life events. 
Many studies have mentioned about the unfavorable effect of psycholog-
ical stress on migraine (35,36). Galego et al. (23) compared the presence 
of stress and SF-36 scores; they suggested that scores of all scales except 
for physical functioning were significantly low and that stress impairs qual-
ity of life. 
The mean number of life events was found to be unrelated with head-
ache duration, duration of chronic headache and severity of headache in 
the MOH and EM groups. On the other hand, significant correlation was 
found between the number of life events and the duration before conver-
sion of headache to a chronic type in the CM group without MOH. On 
the basis of these results, it can be suggested that number of stressful life 
events plays a role in the conversion of headache to the chronic type but 
not associated with the development of medication overuse. 
Stressful life events have usually been compared by being classified as 
minor/major and childhood/adulthood events. De Benedittis et al. (21) 
and Fernandez et al. (22) found that minor life events (daily hassles) are 
more common than major life events and they are significantly associated 
with frequency and severity of headache. In the present study, stressful 
life events were divided into four groups, i.e., economic, personal, health 
and familial, with a different classification; then, these events were com-
pared both between themselves, with the SF-36 subscale scores and with 
headache characteristics. Although the most common stressful life events 
were of personal origin in all three groups, the least common events were 
of familial origin in the MOH patients and of economic origin in the EM 
group. Absence of statistically significant difference between the groups 
suggests that the cause of stressful life events does not play a role in med-
ication overuse or the conversion of headache to a chronic type. Famil-
ial life events were found to be associated with the scores of body pain 
subscale of quality of life. This can be explained by strong family bonds in 
Turkish population.
In the literature, studies on quality of life in migraine patients have demon-
strated impaired quality of life but in different fields. Bussone et al. (37) 
conducted a study in Italy and determined that all subscales of quality of 
life were impaired in CM patients compared with healthy controls. D’Am-
ico et al. (38) reported that both physical and mental subscales of quality 
of life were impaired and occupational and social activities were hindered 
in the groups with CM and medication overuse. In a population-based 
study from United Kingdom, comparing migraine patients with healthy in-
dividuals revealed a significant decrease in all SF-36 subscale scores except 
for general health (13).
In the literature, studies assessing quality of life in patients with MOH are 
few. These studies report that quality of life is impaired in MOH patients 
(14,39,40). Guitera et al. (41) determined impairment in all fields of quali-
ty of life and more significant impairment in physical functioning and body 
pain were observed in MOH patients compared with patients without 
MOH. In the study conducted by D’Amico et al. (38) in Italian patients, 
statistically significant impairment was determined in almost all fields of 
quality of life in patients with CM+MOH. In the present study, it was de-
termined that quality of life was impaired in the fields of general health, 236
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Table 2. Comparison of SF-36 scores in patients with MOH, CM and EM groups
 MOH (n=64) CM (n=25) EM (n=25)
 Median   Median  Median   p group  p group  p group  
 (Min-Max) (Min-Max) (Min-Max) p 1 and 2 1 and 3 2 and 3
Number of SLE 5 (0-13 5 (0-11) 3 (0-8)  .582 .008 .09
Physical functioning 26 (15-30) 26 (15-54) 28 (16-30) .837 .943 .568 .646
Physical role limitation  5 (4-8) 6 (4-8) 7 (4-8) .070 .501 .024 .135
Body Pain 5 (2-10) 6 (3-9) 7 (4-12) .002 .093 .0001 .172
General Health 14 (5-22) 14 (5-22) 17 (6-24) .131 .725 .043 .199
Energy 11 (4-20) 12 (7-19) 14 (7-20) .304 .954 .183 .132
Social functioning 6 (2-10) 6 (3-10) 7 (5-10) .013 .637 .004 .040
Emotional role limitation  4 (3-6) 4 (3-6) 5 (3-6) .764 .725 .629 .444
Mental health 16 (5-26) 15 (10-25) 18 .300 .868 .176 .144
p: Kruskal–Wallis test (p<.05). p group 1 and 2, p group 1 and 3, p group 2 and 3: Post-hoc Mann–Whitney U test (p≤.017 Bonferroni correction). MOH: medication-overuse headache; 
CM: chronic migraine; EM: episodic migraine
Table 3. Distribution of the stressful life events number in MOH, CM 
and EM groups
 MOH  CM EM
 (n=64) (n=25) (n=25) Total
Stressful life events n (%) n (%) n (%) n (%)
1-5 32 (50) 13 (52) 16 (59.3) 61 (52.6)
6-10 28 (43.8) 9 (36) 8 (29.6) 45 (38.8)
11+ 3 (4.7) 1 (4) 0 (0) 4 (3.4)
Chi-square test: n (%). MOH: medication-overuse headache; CM: chronic migraine; EM: 
episodic migraine
role-physical, body pain and social functioning in patients with MOH, but 
there was no difference with CM patients.
The present study found that psychiatric comorbidities are more com-
mon in the MOH group but that, unlike previously reported data, these 
comorbidities showed no significant correlation with quality of life. In the 
literature, that presence of anxiety, depression and stress was reported 
to unfavorably influence quality of life in patients with chronic headache 
(12,23,42). Hung et al. (43) determined significant impairment particularly 
in the physical functioning and energy (vitality) fields of quality of life in 
migraine patients with depression as a comorbidity. 
In the literature depression and anxiety as comorbidities are reported 
to be more common in MOH patients and are attributed to medication 
overuse and the conversion of headache to a chronic type (24,25,44). 
However, in our literature review, we found no study conducted focusing 
on this issue in MOH patients. In the present study, patients with MOH, 
CM and EM were compared in terms of prevalence of depression, anxiety 
and somatoform disorders, as well as the correlation between psychiatric 
comorbidities and quality of life; however, no significant correlation was 
found. We attributed this result to the facts that the diseases in all three 
groups were chronic, proportion of comorbidities were similar and each 
group had a limited number of patients. Previous studies found that symp-
toms of obsessive–compulsive disorder are more common in MOH and 
CM patients than in EM patients and the control group with more preva-
lent obsessive–compulsive personality character found in MOH patients, 
which is consistent with results of the present study (45,46). 
In the present study, in contrast to the EM group, it was found that scores 
of role-physical, general health, social functioning and body pain subscales 
of quality of life were decreased in the MOH group, but there was no 
difference with CM patients who had no medication overuse. It was also 
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Table 4. Correlation between number of stressful life events and SF-36 scores
 Group 0 Group 1 Group 2 Group 3 Total 
 Median (Min–Max) Median (Min–Max) Median (Min–Max) Median (Min–Max) Median (Min–Max) P
Physical functioning 26 (23-29) 28 (15-54) 26 (15-30) 20.5 (18-30) 26 (15-54) .837
Physical role limitation 5 (5-8) 6 (4-8) 6 (4-8) 7.5 (5-8) 6 (4-8) .07
Body pain 7.1 (5-7) 6.1 (2-12) 5.2 (2-9) 5.05 (4-8) 5.2 (2-12) .002
General health 13.4 (9-17) 15 (6-24) 13 (5-21) 12.2 (9-17) 14 (5-24) .131
Energy 15 (8-20) 12 (5-19) 10 (4-20) 8 (4-12) 12 (4-20) .304
Social functioning 7 (5-9) 7 (3-10) 7 (2-10) 4.5 (4-9) 7 (2-10) .013
Emotional role limitation 5 (3-6) 5 (3-6) 3 (3-6) 4 (3-6) 4 (3-6) .764
Mental health 20 (12-24) 17 (8-26) 14 (5-26) 12.5 (7-17) 16 (5-26) .3
p: Kruskal–Wallis test (p<.05). Post-hoc Mann–Whitney U test (p≤.017 Bonferroni correction). Group 0: no event, Group 1: 1–5 events, Group 2: 6–10 events and Group 3: ≥11 events
Table 5. Distribution of stressful life events in MOH, CM and EM groups
                    MOH                CM               EM               Total  
Stressful life events n % n % n % n %
Trouble with chief and colleagues 7 12.28 3 13.64 2 9.09 12 11.88
Change in sleeping habits 32 56.14 15 68.18 12 54.55 59 58.42
Extreme borrowing 10 17.54 5 22.73 3 13.64 18 17.82
To look at elderly or sick relatives at home 6 10.53 4 18.18 1 4.55 11 10.89
Conflicts with parents  6 10.53 2 9.09 0 0.00 8 7.92
Menopause 17 29.82 2 9.09 5 22.73 24 23.76
Severely sick or injury 10 17.54 3 13.64 4 18.18 17 16.83
Major change in eating habits  15 26.32 7 31.82 9 40.91 31 30.69
Major change in living conditions 9 15.79 3 13.64 2 9.09 14 13.86
Major change in social activities  10 17.54 4 18.18 2 9.09 16 15.84
Mild disease of children 5 8.77 1 4.55 3 13.64 9 8.91
Moderate discussions with the partner 14 24.56 7 31.82 2 9.09 23 22.77
To prepare for a difficult exam  6 10.53 4 18.18 2 9.09 12 11.88
Sexual problems  11 19.30 5 22.73 3 13.64 19 18.81
Mild borrowing  9 15.79 2 9.09 3 13.64 14 13.86
Chi-square test: n (%). MOH: medication-overuse headache; CM: chronic migraine; EM: episodic migraine
found that familial stressful life events are important for the individual to 
feel pain. Moreover, different from the literature, absence of significant 
correlation between comorbidities and quality of life despite higher prev-
alence of psychiatric comorbidities in MOH patients is another important 
finding. In the light of these findings, it can be suggested that number of 
stressful life events might be a risk factor for conversion of headache to 
a chronic type. 
On the basis of the results of the present study, it can be concluded that 
the detection and eliminations of stressors in MOH patients may lead to 
significant improvement in controlling headache and enhancing quality of 
life. In addition, preventing or decreasing medication overuse may con-
tribute to the decrease in the burden on both the economy and hospital 
sources and the decrease in potential metabolic problems that medications 
might cause in the patients. For these reasons, it is important to follow up 
the patients who present to neurology policlinics with headache, with or 
without medication overuse, in collaboration with psychiatry clinics. 
The present study has limitations such as a cross-sectional design, the 
method of sample selection, pain characteristics, limited patient number, 
obtaining information on drug use via the patients’ recall and self-rating 
scales. However, the study highlights the importance of a multidisciplinary 
approach to the common health problem of headache, while providing 
preliminary information for future larger studies, which could shed fur-
ther light on the problem. 
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